A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

导出原文传递

翻译打印收藏纠错

作者： Sehn,L.H. ^[1] ; Assouline,S.E. ^[2] ; Stewart,D.A. ^[3] ; Mangel,J. ^[4] ; Gascoyne,R.D. ^[5] ; Fine,G. ^[6] ; Frances-Lasserre,S. ^[7] ; Carlile,D.J. ^[8] ; Crump,M. ^[9]

作者单位： F. Hoffman-La Roche Ltd., Basel, Switzerland ^[1] Roche Products Ltd., Welwyn Garden City, United Kingdom ^[2] British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada ^[3] London Health Sciences Centre, London, ON, Canada ^[4] Genentech Inc., South San Francisco, CA, United States ^[5] Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON, Canada ^[6] British Columbia Cancer Agency, Centre for Lymphoid Cancer, University of British Columbia ^[7] Jewish General Hospital, Montreal, QC, Canada ^[8] Tom Baker Cancer Centre, Calgary, AB, Canada ^[9]

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Blood

2012年119卷22期

5118-5125页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

Blood

相似文献

Blood

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

Blood

相似文献

Blood

相关期刊

检索历史清除